Marron Robert M, Zheng Matthew, Fernandez Romero Gustavo, Zhao Huaqing, Patel Raj, Leopold Ian, Thomas Ashanth, Standiford Taylor, Kumaran Maruti, Patlakh Nicole, Stewart Jeffrey, Criner Gerard J
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States.
Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States.
Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):255-268. doi: 10.15326/jcopdf.2020.0200.
Comorbid disease is a risk factor for severe coronavirus disease 2019 (COVID-19) infection. However, initial rates of chronic obstructive pulmonary disease (COPD) in case series were low and severity of COVID-19 in COPD patients was variable.
We performed a retrospective study of patients admitted with COVID-19 and evaluated outcomes in those with and without COPD and/or emphysema. Patients were identified as having COPD if they had a diagnosis in the medical record and a history of airflow-obstruction on spirometry, or a history of tobacco use and prescribed long-acting bronchodilator(s). Computed tomography scans were evaluated by radiologists. Propensity matching was performed for age, body mass index (BMI), and serologic data correlated with severity of COVID-19 disease (D-dimer, C-reactive protein, ferritin, fibrinogen, absolute lymphocyte count, lymphocyte percentage, and lactate dehydrogenase).
Of 577 patients admitted with COVID-19, 103 had a diagnosis of COPD and/or emphysema. The COPD/emphysema cohort was older (67 versus 58, <0.0001) than the other cohort and had a lower BMI. Among unmatched cohorts those with COPD/emphysema had higher rates of intensive care unit (ICU) admission (35% versus 24.9%, =0.036) and maximal respiratory support requirements, with more frequent invasive mechanical ventilation (21.4% versus 11.8%), but no significant difference in mortality. After propensity-matching there was no difference in ICU admission, maximal respiratory support requirements, or mortality. Univariate and multivariate regression analyses yielded similar results.
Our propensity-matched retrospective cohort study suggests that patients hospitalized with COVID-19 who have COPD and/or emphysema may not have worse outcomes than those without these comorbid conditions.
合并症是2019冠状病毒病(COVID-19)严重感染的一个风险因素。然而,病例系列中慢性阻塞性肺疾病(COPD)的初始发病率较低,且COPD患者中COVID-19的严重程度各不相同。
我们对因COVID-19入院的患者进行了一项回顾性研究,并评估了合并或未合并COPD和/或肺气肿患者的预后。如果患者病历中有诊断记录且肺功能测定显示有气流阻塞病史,或有吸烟史并开具了长效支气管扩张剂,则被确定为患有COPD。计算机断层扫描由放射科医生进行评估。对年龄、体重指数(BMI)以及与COVID-19疾病严重程度相关的血清学数据(D-二聚体、C反应蛋白、铁蛋白、纤维蛋白原、绝对淋巴细胞计数、淋巴细胞百分比和乳酸脱氢酶)进行倾向匹配。
在577例因COVID-19入院的患者中,103例被诊断为COPD和/或肺气肿。COPD/肺气肿队列比其他队列年龄更大(67岁对58岁,<0.0001),且BMI更低。在未匹配队列中,患有COPD/肺气肿的患者重症监护病房(ICU)入院率更高(35%对24.9%,P=0.036),对最大呼吸支持的需求更高,有创机械通气更频繁(21.4%对11.8%),但死亡率无显著差异。倾向匹配后,ICU入院率、最大呼吸支持需求或死亡率均无差异。单因素和多因素回归分析得出了类似结果。
我们的倾向匹配回顾性队列研究表明,因COVID-19住院且患有COPD和/或肺气肿的患者,其预后可能并不比没有这些合并症的患者更差。